Treatment of Behçet’s Disease Complicated by Pulmonary Artery Aneurysms

This protocol covers Behçet’s syndrome presenting with pulmonary artery aneurysms — a serious vascular manifestation that defines a distinct clinical subgroup requiring a targeted management approach.

Clinical Scenario

Pulmonary artery aneurysms represent one of the most severe vascular complications in Behçet’s syndrome. Their presence calls for specific intervention that differs from the general management of the disease.

Treatment Approach — Partial Overview

In cases that are refractory to initial management, the protocol includes a targeted biologic therapy. The complete selection criteria, agent details, and clinical algorithm are available in the full protocol.

Full regimen, dosing, and sequencing not shown here — access the complete protocol below.

Instant Access to Structured Evidence-Based Regimens

References

For the management of pulmonary artery aneurysms, high-dose glucocorticoids and cyclophosphamide are recommended.

Monoclonal anti-TNF antibodies should be considered in refractory cases.

Observational, uncontrolled evidence showed that infliximab provided benefit in some of the refractory patients.

DOI: 10.1136/annrheumdis-2018-213225 View source ↗